This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Exelixis Announces Data Presentations At ESMO 2012 Congress

Stock quotes in this article: EXEL

Exelixis, Inc. (NASDAQ: EXEL) today announced that its lead compound, cabozantinib, will be the subject of three clinical data presentations at the European Society for Medical Oncology (ESMO) 2012 Congress. During the meeting, which will be held from September 28 to October 2, 2012, in Vienna, Austria, investigators will present data from ongoing trials of cabozantinib in medullary thyroid cancer, castration-resistant prostate cancer, and non-small cell lung cancer.

The full roster of cabozantinib data presentations expected at the meeting is as follows (all times Central European):

Oral Presentation

  • “Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 non-randomized expansion cohort (NRE)” (Abstract #897O)Dr. Johann de Bono, Royal Marsden Hospital & Institute of Cancer Research, Sutton, UKOral abstract session: Genitourinary tumors, prostate ISunday, September 30, 201211:45 a.m. CESTHall D

Poster Discussions

  • “Molecular profile and anti-tumor activity in non-small cell lung cancer (NSCLC) patients (pts) in a phase 1 study of cabozantinib (XL184) in Japan” (Abstract #1708PD)Dr. Hiroshi Nokihara, National Cancer Center Hospital, Tokyo, JapanPoster discussion session: Developmental therapeuticsSunday, September 30, 2012Poster on display starting at 9:30 a.m. CEST; respective discussion session starting at 1:00 p.m.Hall H
  • “Clinical activity and pharmacokinetics (PK) of cabozantinib (XL184) in patients with progressive medullary thyroid carcinoma (MTC)” (Abstract #445PD)Dr. Ezra Cohen, University of Chicago, Chicago, ILPoster discussion session: Developmental therapeuticsSunday, September 30, 2012Poster on display starting at 9:30 a.m. CEST; respective discussion session starting at 1:00 p.m.Hall H

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (formerly known as XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs